PD-L1 antibody

Phase 1Small molecule

WWest China Hospital

PD-L1 antibody is one of 73 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cervical CancerActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Cervical CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

PD-L1 Antibody

NCT06742424

Q2 2033

Phase 2/3Recruiting

Cervical Cancer

NCT07472153

Clinical

Trials by Indication[1]

PD-L1 Antibody1 trial

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Recruiting·WWest China Hospital·Phase 2·NCT06742424·36 enrolled

Lymphoma1 trial

Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Unknown status·HHitGen Inc.·Phase 1·NCT04977167·96 enrolled

Cervical Cancer1 trial

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Recruiting·NN.N. Alexandrov National Cancer Centre·Phase 2/3·NCT07472153·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PD-L1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-L1 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-L1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWest China Hospital

PD-L1 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2033

Trials by Indication[1]

PD-L1 Antibody1 trial

Lymphoma1 trial

Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News